ADAP - Adaptimmune Therapeutics Plc's (ADAP) CEO Adrian Rawcliffe On Q4 2021 Results - Earnings Call Transcript

Adaptimmune Therapeutics plc (ADAP) Q4 2021 Earnings Conference Call March 14, 2022 8:30 A.M. ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Officer John Lunger - Chief Patient Supply Officer Helen Tayton-Martin - Chief Business Officer Karen Miller - Senior Vice President, Pipeline Research Gavin Wood - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Nick Abbott - Wells Fargo Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear. The machine-assisted output provided is partly edited and is designed as a guide. Presentation Operator 00:04 Good day. Thank you for standing by. Welcome to the Full-Year and Fourth Quarter 2021 Adaptimmune Earnings

For further details see:

Adaptimmune Therapeutics Plc's (ADAP) CEO Adrian Rawcliffe On Q4 2021 Results - Earnings Call Transcript